Advertisement

New HTA Policy in Japan

  • Isao Kamae
Chapter

Abstract

Some in Japan and outside Japan have suggested that Japan is a country that has “lagged behind” and that there is no HTA and in particular no value-based pricing for pharmaceuticals (VBP) in Japan because Japan has failed to stay current with the trend toward pharmacoeconomics that originated in Europe and the USA. Although it is true that Japan does not have a system for value-based medicine (VBM) and VBP which evolved from evidence-based medicine and is now prominent in Europe and the USA, a pricing policy which can be referred to as the Japanese model of VBP has historically in Japan. As discussed in Sect.  1.1, the healthcare system in Japan already includes a complex process of HTA applied at the level of macro-technologies, as described by Towse et al., and that process has continued with healthcare reforms started under the Koizumi administration through the administrations of the Democratic Party of Japan and the Abe administration, with a shift in the focus of reforms onto the aging population. Moreover, a “Japanese model” of HTA has also developed at the level of microtechnologies, as seen in Japan’s distinctive pricing policy. As such, the claim that Japan is an “HTA-underdeveloped country” is based on a misguided view stemming from a lack of understanding of the past and present situation of the Japanese healthcare system as a whole and its pricing policy.

References

  1. 1.
    Mahlich J, Kamae I, Rossi B (2017) A New Health Technology Assessment System for Japan? Simulating the potential impact on the price of Simeprevir. Int J Technol Assess Health Care 33(1):121–127CrossRefGoogle Scholar
  2. 2.
    Kamae I, Kobayashi M (2010) Value-based pricing of new drugs in japan using the principle of incremental cost-effectiveness ratio. ISPOR Connect 16(4):9–10Google Scholar
  3. 3.
    Kamae I, Murata T, Suman D, Yamabe K, Sugimoto T, Kobayashi M (2013) The survey of the japan-style premium scheme in pharmaceutical pricing decisions. ISPOR 16th annual European congress, Dublin, 5 Nov 2013Google Scholar
  4. 4.
    Central Social Insurance Medical Council Special Committee on Cost-Effectiveness. Pilot implementation of cost-effectiveness evaluation, cost-1, 16 Dec 2015 (in Japanese). http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000107178.pdf. Accessed 21 Jul 2017
  5. 5.
    Kamae I (2017) New system on health technology assessment in Japanese Ministry of Health, Labour and Welfare: (1) pilot introduction of ‘cost-effectiveness’ evaluation. Pharm Med Device Regulat Sci 48(2):82–88. (in Japanese)Google Scholar
  6. 6.
    Kamae I (2017) New system on health technology assessment in Japanese Ministry of Health, Labour and Welfare: (2) how to make a decision on whether cost-effective or not. Pharm Med Device Regulat Sci 48(4):215–220. (in Japanese)Google Scholar
  7. 7.
    Kamae I (2017) New system on health technology assessment in Japanese Ministry of Health, Labour and Welfare: (3) how to reflect the cost-effectiveness in pricing. Pharm Med Device Regulat Sci 48(7):452–459. (in Japanese)Google Scholar
  8. 8.
    Kamae I (2017) New system on health technology assessment in Japanese Ministry of Health, Labour and Welfare: (4) how to attain the sustainability of the system. Pharm Med Device Regulat Sci 48(9):588–593. (in Japanese)Google Scholar
  9. 9.
    Shiroiwa T, Fukuda T, Ikeda S, Takura T, Moriwaki K (2017) Development of an official guideline for the economic evaluation of drugs/medical devices in Japan. Value Health 20(3):372–378CrossRefGoogle Scholar
  10. 10.
    The Study Team (2016) (Team Leader: Fukuda T) for “Establishing evaluation methods, data standardization, and assessment systems toward the application of economic evaluation of healthcare technologies to governmental policies.” Guideline for preparing cost-effectiveness evaluation to the Central Social Insurance Medical Council. Version 1.0. https://www.ispor.org/PEguidelines/source/Japanese_PE_Guideline.pdf. Accessed 9 Mar 2018
  11. 11.
    Central Social Insurance Medical Council Special Committee on Cost-Effectiveness (2017) Special Committee on Drug Pricing, Special Committee on Health and Medical Devices (the 5th meeting). Response to the issues raised in the pilot implementation of cost-effectiveness evaluation (other issues). Cost/Drug/Device-2 (in Japanese). http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000184180.pdf. Accessed 8 Jan 2018
  12. 12.
    Central Social Insurance Medical Council Special Committee on Drug Pricing (2017) (The 140th meeting). Fundamental reform of the drug pricing system (proposal), Drug-1 (in Japanese). http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000185617.pdf. Accessed 8 Jan 2018.
  13. 13.
    Central Social Insurance Medical Council Special Committee on Drug Pricing (2017) Outline of the fundamental reform of the drug pricing system: appendix (proposal), drug-2. The 143th meeting, 20 Dec 2017 (in Japanese). http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000188705.pdf. Accessed 8 Jan 2018
  14. 14.
    Central Social Insurance Medical Council Special Committee on Drug Pricing (2017). Fundamental reform of the drug pricing system (proposal), drug-2. The 140th meeting, 22 Nov 2017 (in Japanese) http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000188612.pdf. Accessed 8 Jan 2018
  15. 15.
    Cabinet Office. The 2017 Basic Policy on Economic and Fiscal Management and Reform: increasing productivity through investment on human resources” (Big-Boned Policy), outline of the 2017 Basic Policy on Economic and Fiscal Management and Reform (in Japanese). http://www5.cao.go.jp/keizai-shimon/kaigi/cabinet/2017/2017_basicpolicies_ja.pdf. Accessed 5 Jan 2018
  16. 16.
    Lakdawalla DN, Doshi JA, Garrison LP, Phelps CE, Basu A, Danzon PM: Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]. Value in Health 21(2):131-139, February 2018. https://www.valueinhealthjournal.com/article/S1098-3015(17)33892–5/pdf [Accessed December 24, 2018]CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Isao Kamae
    • 1
  1. 1.Graduate School of Public PolicyThe University of TokyoTokyoJapan

Personalised recommendations